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'In the middle of difficulty lies opportunity' 
Albert Einstein 
  
 
   
ABSTRACT 
Tumor tissues contain diverse cell populations that relentlessly cross-communicate with each 
other in the tumor microenvironment. In addition to malignant cells, infiltration of other host 
cells including inflammatory cells, fibroblasts, and cells in the vessel walls in tumors 
significantly contribute to tumor growth and metastasis. The diversity of cell populations in the 
tumor microenvironment determines the production of various growth factors and cytokines, 
which are often upregulated. Although these signaling molecules interact with their specific 
receptors to trigger signaling events in the targeted cells, they often crosstalk to each other to 
elicit additive or synergistic effects in the tumor tissue. This thesis work provides several 
examples of such complex interactions between various cellular and signaling components in 
the tumor microenvironment in promoting metastasis. We particularly focused our research on 
angiogenesis-related signaling events to identify molecular mechanisms underlying tumor 
metastasis. In paper I, we show that expression levels of PDGF-BB in tumor cells can serve as 
a surrogate marker for drug response. One of the most surprising findings is that high levels of 
tumor cell-derived PDGF-BB ablates pericytes from the tumor microvasculature. 
Mechanistically, tumor cell-derived PDGF-BB attracts pericytes from the vessel wall toward 
tumor cells, leaving the endothelium unprotected. Ablation of pericytes leads to exposure of 
primitive microvessels susceptible for tumor cell intravasation. As a result, inhibition of the 
PDGF-BB-PDGFR signaling in high PDGF-BB-producing tumors prevents tumor cell 
intravasation and metastasis. Conversely, inhibition of the PDGF-BB-PDGFR signaling in 
PDGF-BB negative tumors ablates pericytes from the tumor microvasculature and promotes 
tumor metastasis. Therefore, PDGF-BB levels may serve as a potential surrogate marker for 
predicting anti-PDGF therapeutic outcomes. In paper II, we uncover a novel mechanism of 
pericytes in promoting tumor metastasis. In PDGF-BB-activated pericytes, genome-wide 
profiling shows that IL-33 is the most upregulated gene among all genes. ST2 as a receptor for 
IL-33 is abundantly expressed in macrophages. In various in vitro and in vivo experimental 
settings, IL-33 promotes the polarization of macrophages to an M2 subtype. Gain- and loss-of-
function experimental data show that IL-33-activated macrophages promote tumor metastasis. 
Together, this work reveals a previously unknown mechanism underlying pericyte-mediated 
tumor metastasis and targeting the PDGF-PDGFR-IL-33-ST2 signaling axis provides a novel 
therapeutic option for treatment of cancer patients. Paper III identifies VEGF-B; a VEGFR-1 
exclusive binding ligand, as a promoter of tumor metastasis through a VEGF-A-independent 
mechanism. VEGF-B remodels tumor vessels to become pseudonormalized and highly leaky 
by ablating pericytes from tumor vessels. The highly leaky tumor vessels permit tumor cell 
intravasation into the circulation and facilitate metastasis. Importantly, high expression levels 
of VEGF-B in cancer patients correlate with poor prognosis. In the last paper, we show that 
FGF-2 and VEGF-C collaboratively promote lymphangiogenesis. For the first time, we show 
that the VEGFR3 signaling is crucial for non-VEGF-C-induced lymphatic networks. 
Importantly, FGF-2 and VEGF-C synergistically promotes metastasis. Altogether, this thesis 
work uncovered several novel mechanisms underlying tumor metastasis and targeting these 
signaling pathways may offer new opportunities for effective treatment of cancer patients.  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Cancer är en sjukdom som drabbar allt fler människor världen över och där dödligheten är 
fortsatt väldigt hög. Den främsta orsaken till att patienter dör, är att sjukdomen spridits till flera 
organ i kroppen via en process som kallas metastasering. Idag finns det ingen effektiv 
behandling för patienter som utveckar metastaser. En målsättning med den här avhandlingen 
är att med ny kunskap kunna utveckla bättre behandling av dessa patienter. En tumör uppstår 
på grund av okontrollerad tillväxt av celler som överlever trots att dom inte borde. Dessa 
växande celler klarar sig dock inte på egen hand, utan behöver hjälp från andra typer av celler 
som tillsammans utgör den så kallade mikromiljön. Här finner man celler som bygger upp 
blodkärl och lymfkärl, stödceller, celler i bindväven, samt immunceller. Utöver celler, spelar 
även lösliga faktorer stor roll för uppbyggnaden av tumörer. Det sker intensiv kommunikation 
och samarbete mellan alla dessa delar och det påverkar hur tumörer växer, sprider sig, samt hur 
väl dom svarar på behandling. Idag har vi endast begränsad kunskap om detta samspel. I det 
beskrivna arbetet har vi lyckats samla information om sådana samspel. Den växande massan 
bestående av tumörceller behöver konstant inflöde av syre och näring, vilket sker med hjälp av 
blodkärl. Man vet att tillväxt av nya blodkärl i tumörer är avgörande för tumörens överlevnad. 
Spridning av tumörceller kan ske lokalt till närliggande vävnader, men vanligtvis sker det via 
kärlsystemen. Blodkärl kan ses som ett rör med flera skyddande lager på utsidan. Ett av dessa 
skyddande lager utgörs av så kallade stödceller som har i uppgift att skydda kärlen och 
förhindra läckage. Tumörceller har väldigt svårt att bryta detta lager och kan normalt sett inte 
ta sig in i blodkärlen. Det finns dock olika sätt som detta skyddande lager kan försämras och 
ge tumörcellerna en chans att ta sig in blodkärlen och vidare sprida sig till andra organ. Vi har 
påvisat hur tumörceller direkt kan producera lösliga faktorer som leder till ett försämrat 
skyddande lager. Som ett resultat, fann vi att tumörer började växa i lungor och i lever. 
Tumörceller är som fabriker där allt möjligt tillverkas. Celler i omgivningen påverkas av olika 
saker som produceras. Vi har funnit hur stödcellerna runt blodkärl kan utbildas av tumörceller 
till att aktivt bidra till att underlätta spridning av tumörceller. Som i många fall när det kommer 
till cancer, så är förklaringen till ett visst beteende väldigt komplicerat. Ha i åtanke att det, som 
tidigare nämnt, sker intensiv kommunikation mellan olika delar i mikromiljön. I stora drag: 
Tumörceller påverkar mängden och kvalitén på blod- och lymfkärl  tumörceller har lättare 
tillgång till blodkärl  metastaser 
Tumörceller påverkar immunceller  immunceller hjälper tumörceller att sprida sig via 
blodkärl  metastaser 
Tumörceller kommunicerar med stödceller runt blodkärl  stödceller påverkar immunceller 
 immunceller hjälper tumörceller att sprida sig via blodkärl  metastaser 
Genom den kunskapen vi bidrar till att utöka, kan vi hitta nya sätt för behandling av 
cancerpatienter. Samt underlätta valet av behandling som bör ges till en viss patient utifrån 
olika kännetecken hos den enskilde individens tumör. 
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1 INTRODUCTION 
1.1 CANCER 
The World Health Organization reported that 8.2 million deaths due to cancer occurred 
worldwide during 2012. These numbers are projected to increase by 75% over the coming two 
decades1. According to recent estimations, about one third (1/3) of the Swedish population will 
suffer from cancer2. 
Cancer is a complex disease that is not restricted to the simple outgrowth of a malignant tumor 
at a single location in the body. Rather, the disease is affecting the host systemically and most 
commonly, tumor cells are spreading throughout the body, forming metastases3. The 
consequences of metastatic growth, ultimately, are the major causes of death for cancer 
patients4. To reduce mortality, additional efforts are necessary to understand the processes by 
which tumors are spreading, which constitutes one major hurdle in the treatment of cancer 
patients5. This thesis work aimed to reveal mechanisms microenvironmental regulation of 
tumor metastasis. 
 
1.2 HALLMARKS OF CANCER 
The formation of a tumor is an intricate process with a few shared common features, known as 
the hallmarks of cancer. The six hallmarks were first described by Hanahan and Weinberg in 
2000, and later revisited in 2011 when four additional features were included6. Three of the 
hallmarks are specifically addressed in this current thesis; 1) induction of vessel growth by 
angiogenesis, 2) generation of a tumor-promoting microenvironment, and 3) metastasis (Figure 
1). These hallmarks will be discussed in detail throughout the thesis. 
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Figure 1. The hallmarks of cancer. 
 
1.3 ANGIOGENESIS 
There are multiple steps that are crucial during the formation of a solid tumor. Understanding 
how angiogenesis and modulation of blood vessels promotes tumor metastasis was of central 
focus of the current study. Angiogenesis is a process based on a sprouting principle where 
committed endothelial cells (ECs) from a pre-existing vessel are instructed to form new 
vessels7. The concept of tumor angiogenesis was initiated by Dr. Judah Folkman in 1971. He 
hypothesized that tumor masses would require additional blood supply to sustain their growth 
beyond 2 mm³, and that tumors are able to initiate vessel growth8. Tumors that fail to induce 
such blood vessel growth will regress or remain at a dormant stage. The field of anti-angiogenic 
targeting therapy was initiated based on this theory, and will be discussed further in sections 
1.8.2 and 1.9.  
As the tumor mass continues to grow, it transitions from a stage of being avascular (lacking 
blood vessels), to being able to induce the first sprout, subsequently experiencing enhanced 
growth with continuous increase in the intratumoral vascularity9 (Figure 2).  
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Figure 2. Stepwise growth of new blood vessels into the growing tumor mass by 
angiogenesis. 
 
Coordinated events are required to permit sprouting of a quiescent vessel. The majority of 
mature vessel consists of multiple layers surrounding the inner EC layer, including mural cells 
and a basement membrane10. The basement membrane is a unique part of the extracellular 
matrix (ECM), mainly composed of laminin and collagen, and provides stability for the vessel, 
as well as playing a crucial role for EC survival11, 12. When angiogenesis is initiated, this fibrous 
structure needs to be degraded by ECM enzymes; the proteases13. Upon receiving the 
appropriate signals, one selected cell from each branch-point, the tip EC, will extend filopodia, 
start migrating towards the angiogenic stimuli and lead the way for the sprout. Following this 
tip cell are cells known as stalk cells that mainly proliferate and produce ECM to form and 
stabilize the new vessel14.  
Angiogenesis is, however, not restricted to tumor tissues. On the contrary, the mode of 
generating new vessels by sprouting angiogenesis is essential for various physiological 
processes, such as in developmental tissues in the embryo, during wound healing, and for the 
reproductive system7, 15, 16. If the angiogenic process is not occurring within certain limitations, 
it can lead to the development of diseases or even be lethal. In addition to cancer, dysregulated 
blood vessel growth is involved in the pathology of atherosclerosis, obesity, and retinopathy9, 
17, 18. The blood system is vital as its main functions are to supply oxygen and nutrients, as well 
as removing metabolic waste products from tissues. Although the basis of angiogenesis during 
physiology and pathology is very similar and involves many of the same steps, the vascular 
outcome is, importantly, quite different in a tumor compared to healthy tissues. The capillaries 
that are formed during the tightly regulated angiogenic process occurring in healthy tissues are 
organized and smooth19. They are usually well-balanced, commonly characterized by high 
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perfusion and low permeability owing to high coverage with mural cells, such as pericytes 
(PCs) and vascular smooth muscle cells (VSMCs), as well as an intact basement membrane12, 
20. Although there are exceptions and some healthy vessels are relatively leaky. In the tumor, 
the angiogenic process lacks tight regulation and thereby generating a rather immature vascular 
network consisting of disorganized, leaky, and, in many cases, dysfunctional vessels21, 22. The 
perivascular coverage of these vessels is often poor23, 24. Consequently, the structure facilitates 
intra- and extravasation of cells to and from the tissue, hence, increasing the possibility of 
metastatic seeding via the vascular system25, 26. The vascular endothelial growth factor 
(VEGF)-A signaling is the most potent inducer of angiogenesis and will be discussed in detail 
in section 1.6.1.1. 
 
1.4 VASCULAR REMODELING 
The vascular characteristics are not only depending on the active process of angiogenesis. 
Vascular remodeling plays an important role in determining the structure and quality of vessels 
within the tissue, both during physiological processes and under pathological conditions27-29. 
This is important for both the blood and lymphatic systems. The newly formed blood vessel is 
dependent on extracellular signals and support from mural cells for its survival. This provides 
an opportunity for regulating the vascularity by modulating, for example, the perivascular 
coverage. Several factors have been reported to have vascular remodeling properties30, 31. One 
of the most potent family of proteins that has been widely studied in this context, is the 
angiopoietin (Ang) family consisting of four identified members, the Ang-1-432, where Ang-1 
and -2 have received most attention so far. By interacting with their receptor tyrosine kinases 
(RTKs), namely Tie-1 and Tie-2, Ang-1 and -2 have been shown to have opposing functions. 
Ang-1 plays a role in vessel stability and maturation by providing adhesion and survival 
signals. On the contrary, Ang-2 is promoting vascular de-stabilization and regression by 
ablating the perivascular coverage, thereby removing the support-system33. Ultimately, the 
balance between Ang-1 and Ang-2 determines vascular stability and provides an opportunity 
to fine-tune the vascular remodeling according to the need of the tissue.  
In addition, as discussed later in sections 1.6.1.2 and 1.6.2.1, as well as in Papers I and III, some 
other common growth factors expressed in tumors, such as VEGF-B and platelet-derived 
growth factor (PDGF)-BB, are also exerting their functions by vascular remodeling. 
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1.5 LYMPHANGIOGENESIS 
Alongside the development of a blood vasculature system, lymphatic vessels are 
simultaneously formed in a process known as lymphangiogenesis34-36. In contrast to the blood 
system, postnatal lymphangiogenesis does not occur under physiological circumstances, 
however, there can be extensive remodeling37. The lymphatic vascular network is a very 
important system with various functions, including maintenance of tissue homeostasis by 
regulating fluids and macromolecules, and is also involved in the immune system by providing 
means of transportation of immune cells from tissues to lymph nodes where antigen 
presentation is occurring35. Moreover, while the structure of a blood vessel is complex, 
consisting of several layers and secondary cells, the majority of lymphatic vessels are a simple 
assembly of lymphatic ECs (LECs). Although, there are support cells surrounding the large 
lymph vessels too. Unlike the blood system, except the major collective lymphatic vessels, the 
lymphatic system does not need additional support as it has a relatively passive and low 
pressure mode of transportation, relying on contractions of skeletal muscles for its circulation 
of lymphatic fluid38. Importantly, the LECs are forming valves within the vessels to ensure a 
unidirectional flow of fluids39.  
The most common symptom of a malfunctioning lymphatic system is lymphedema, which can 
be the result of insufficient drainage of fluids from tissues leading to swelling. This can either 
be caused by lymphatic hypoplasia due to an inherited genetic mutation, by surgical 
intervention, or as a consequence of infections40. In the tumor tissue, the lymphatic system is a 
common route of tumor dissemination41. The intravascular environment in a lymph vessel is 
less stressful compared to blood vessels, leading to increased chance of tumor cell survival and 
successful distal seeding42. As discussed later in section 1.6.1.3 and Paper IV, the main pro-
lymphangiogenic signaling pathway is VEGF-C/VEGFR3. 
 
1.6 TUMOR-RELATED GROWTH FACTORS 
Many proteins found in tumors are classified as growth factors. Signaling by these factors is 
instrumental for basically all steps in tumor progression. The high frequency of activating-
mutations in growth factor-related genes, e.g. receptors and downstream components, 
commonly found in tumors, is really emphasizing the importance this type of signaling. Some 
proteins are regulating multiple pro-tumorigenic steps, such as epidermal growth factor (EGF) 
which is involved in early clonal expansion, angiogenesis and invasion43, whereas other factors, 
such as VEGF-A mainly regulate angiogenesis. In addition to VEGF-A, several other factors 
have been found to function as positive or negative regulators of angiogenesis44. Under 
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physiological circumstances, the balance is in favor of inhibition, whereas in a pathological 
setting, for instance in a tumor, this balance is skewed. An ‘angiogenic switch’ is required to 
initiate the angiogenic process45.  
 
 
Figure 3. Classical RTK signaling pathways. 
 
The pro-angiogenic growth factors most commonly active in the tumor are ligands that signal 
through RTKs (Figure 3). These receptor proteins are, in general, membrane-bound with a 
single transmembrane domain spanning the plasma membrane. The extracellular domain is 
responsible for ligand recognition and binding, which can occur as monomer or dimer (for 
simplicity, only ligand dimers are illustrated in Figure 3). Upon ligation, the receptor proteins 
will dimerize to form hetero or homodimers. Receptordimerization subsequently leads to 
activation of the intracellular tyrosine kinase domains, which will become phosphorylated and 
activate classical downstream adaptor proteins46-48. Various signaling events are initiated 
depending on the type of extracellular signal received. Biological outcomes involving 
proliferation are generally conveyed through Ras-Raf-MEK-ERK pathway. PI3K-Akt 
activation is related to survival, whereas p38 is responsible for migratory behavior46, 49-52.  
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The three most common and relevant protein families will be introduced in the following 
sections, including: the VEGF-family, PDGF-family, and fibroblast growth factor (FGF)-
family. 
 
1.6.1 Vascular endothelial growth factor (VEGF)-family 
The VEGF family consists of five structurally similar members, namely VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and placenta growth factor (PlGF). To exert their functions, these proteins 
are relying on binding to specific RTKs. There are three different VEGF receptors; R1, R2, and 
R3. VEGFR1, which can also be spliced to generate a soluble, non-membrane bound form, is 
able to bind VEGF-A, VEGF-B, and PlGF53-55. Signaling through this receptor plays a role in 
vascular modulation. Noticeably, the binding affinity of VEGF-A to VEGFR1 is higher 
compared to VEGFR2, whereas the signaling capacity through VEGFR1 is much lower 
compared to VEGFR2. VEGFR1 is therefore also thought to be important in sequestering 
VEGF-A, hence, acting as a negative regulator of angiogenesis56-58. VEGFR2 on the other hand 
is responsible for the most potent pro-angiogenic signal by binding VEGF-A, but VEGF-C and 
VEGF-D are also capable of interacting with this receptor. The last member, VEGFR3, is 
ligated by VEGF-C and VEGF-D59. Activation of this receptor is important for 
lymphangiogenesis and essential for tip cell formation during angiogenesis. In addition to the 
importance for physiological processes, this family of proteins has been shown to play a role 
in other diseases than cancer, such as neurodegenerative disorders, age-related macular 
degeneration, and rheumatoid arthritis9, 60. 
 
1.6.1.1 VEGF-A 
VEGF-A is the most potent pro-angiogenic factor playing instrumental roles under 
physiological and pathological conditions. VEGF-A mainly signals through binding to 
VEGFR2. Global knock-out of either VEGF-A or VEGFR2 is embryonically lethal61-63, 
emphasizing the crucial role of this pathway. Expression of VEGF-A has been found to be 
induced by a wide range of stimuli. In addition to hypoxia-dependent transcription and mRNA 
stabilization, factors such as PDGF, FGF, and EGF are able to effectively regulate VEGF-A 
expression64, 65. As VEGF-A is mainly a mitogen, its primary function in ECs is to promote 
proliferation, but is also involved in migration and survival, hence is important for the overall 
angiogenic process66, 67. One key feature of VEGF-A is its ability to increase vascular 
permeability, which plays a critical role in acute inflammation as well as for angiogenesis68. 
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Noticeably, both the receptor and ligand are expressed by different cell types69, however, an 
interesting study demonstrated that VEGFR2 is largely restricted to the vascular ECs in human 
tumors70. VEGF-A is commonly expressed at elevated levels in both pre-clinical tumor 
models71, 72 and in human tumors73, 74. In the clinical setting, studies have indicated a strong 
correlation between high levels of VEGF-A and poor prognosis in many cancer types, 
including prostate cancer75, breast cancer76, and gastric cancer77. Anti-VEGF therapy will be 
discussed in sections 1.8.2 and 1.9.  
 
1.6.1.2 VEGF-B 
The functions of VEGF-B are not well-studied compared with VEGF-A, and the biological 
roles of its signaling are still controversial. Global deletion of VEGF-B in mice seems to only 
produce minor defects in the heart, such as an atrial conduction abnormality 78, 79. This data 
somewhat diminishes the possibility of VEGF-B playing any critical roles during development. 
VEGF-B interacts with VEGFR1 to transduce its signals, and interestingly, knock-out of 
VEGFR1 is embryonically lethal80. In contrast, when only the intracellular tyrosine-kinase 
domain, responsible for signal transduction, is deleted (VEGFR1-TK), mice are viable, further 
complicating the potential role of VEGFR1-binding ligands81. It should be pointed out that in 
this model, the receptor is still present and able to bind VEGF-A, VEGF-B and PlGF. The 
regulation of VEGF-B expression remains to be elucidated. Common growth factors, cytokines 
and hormones do not seem to be involved, and in contrast to VEGF-A, VEGF-B is not induced 
by hypoxia82, 83. As an endothelial mitogen, VEGF-B is only displaying modest angiogenic 
capacity84. It is debated whether VEGF-B is to be considered pro- or anti-angiogenic85-87. 
Studies have shown that the angiogenic effects of VEGF-B could be a result of modulating the 
VEGF-A signaling88. By activation of VEGFR1, VEGF-B seems to be involved in vascular 
remodeling as its signaling leads to expression of plasminogen activator inhibitor-1 and 
urokinase, both of which are important for protecting the ECM from degradation89, 90. Despite 
an unclear picture of the biological contributions of VEGF-B, one study reported the expression 
of VEGF-B in a wide range of human tumors91, and high expression levels are correlated with 
metastasis in colorectal cancer92, and breast cancer patients93. 
 
1.6.1.3 VEGF-C 
VEGF-C exerts its biological functions mainly through VEGFR3 activation. This member of 
the VEGF family plays an instrumental role in the lymphangiogenic process, but has also been 
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shown to be involved in blood vessel formation94, 95. Experimental data emphasizes the critical 
role of this signaling pathway as it was shown that embryos do not survive until birth when 
VEGF-C is globally deleted; this was due to the lack of lymphatic vessels96. Interestingly, 
VEGFR3 deficient mice die earlier compared to VEGF-C null mice, and in contrast, these mice 
display severe defects in the blood vasculature97. Mechanistically, VEGF-C is a potent driver 
of lymphangiogenesis by promoting lymphatic ECs proliferation, migration and survival84, 98. 
Production of VEGF-C can be upregulated by various growth factors, including PDGF and 
EGF82, or pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α. There is 
conflicting evidence on whether or not hypoxia is involved82, 100-102. One recent publication 
identified hypoxia as an inducer of VEGF-C expression; however, this regulation was hypoxia 
inducible factor (HIF)-1α-independent103. In line with its lymphangiogenic properties, pre-
clinical studies have confirmed the ability to promote intra-tumoral lymphatic growth. For 
example, in a human breast cancer xenograft model, where tumor cells were propagated to 
overexpress VEGF-C, a significant increase in lymphangiogenesis was observed. This was, 
moreover, correlated with lymph node and lung metastases104. VEGF-C has also been 
identified to play a role in human cancer patients. In one extensive study, it was reported that 
VEGF-C mRNA levels could be detected in roughly 50% of cases, including breast cancer and 
melanoma91. Other studies have detected VEGF-C in tumors such as colorectal cancer105, 106, 
gastric cancer107, and esophageal cancer108. Additionally, a link between VEGF-C expression 
and lymph node metastasis was reported for breast cancer109, gastric cancer110, and esophageal 
cancer111, 112. In all the above cases, VEGF-C was also correlated to poor patient prognosis.  
 
1.6.2 Platelet-derived growth factor (PDGF)-family 
The four ligands belonging to the PDGF family mostly form homodimers (AA, BB, CC, and 
DD); however, heterodimerization can also occur resulting in AB dimers. Two different RTK 
protein chains, α and βrespectively, are forming homo- or heterodimers to function as 
receptors. Receptor dimers consisting of ααare able to bind AA, BB, AB, and CC ligands, 
whereas receptor dimers of ββ are binding BB and DD ligands. Various experimental data 
shows that all ligand combinations, except AA, can interact with  receptor heterodimers113. 
Expression of these ligands and receptors can be found in a broad spectrum of cell types, 
including VSMCs, PCs, ECs, and fibroblasts114. The PDGF family is generally important for 
transducing mitogenic as well as chemotactic signals115, 116, thereby playing a role in 
development, wound healing, and tumor angiogenesis, including both hematogenous and 
lymphatic vessel growth113, 117. Evidence for implication of abnormal PDGF signaling has been 
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found in various pathological conditions and processes, including cancer, diabetic 
retinopathy118, and atherosclerosis119, 120. 
 
1.6.2.1 PDGF-B 
PDGF-B is the major factor responsible for the recruitment of PCs and VSMCs to vessels to 
provide necessary support and, hence, is essential for the formation of mature blood vessels121, 
122. Signaling from PDGF-B by activation of its PDGFR-β receptor on PCs and VSMCs is 
essential for proliferation, migration and survival123, 124. The mechanisms of PDGF-B-induced 
angiogenesis are still debated. Experimental data support the finding that PDGF-B directly 
promotes sprouting of ECs in vitro123, 125, however, to date, it has not yet been confirmed in 
vivo117. The indispensable role of PDGF-B signaling in development was realized when global 
knock-out models were generated. Both PDGF-B and PDGFR-β null mice die perinatally due 
to severe hemorrhages, confirming the involvement of PDGF signaling for proper vascular 
development126, 127. In fact, the vascular endothelium, including in tumors, is a key source of 
PDGF-B128. However, importantly, tumor cells also express PDGF-B129. There are multiple 
factors with potential to regulate PDGF-B expression, including TNF-α and transforming 
growth factor (TGF)-β. Hypoxia has also been confirmed to have an important regulatory 
function by stimulating PDGF-B expression132, 133. In the tumor setting, PDGF-B can act either 
directly on tumor cells, or indirectly be promoting tumor progression by its angiogenic 
effects134, 135. In line with the pro-tumorigenic effects of PDGF-B, significant correlations 
between its expression and poor prognosis have been demonstrated in lung cancer136, 137. 
Interestingly, PDGF-B expression has been linked to lymph node metastasis in gastric 
cancer138. Potential of PDGF-targeting therapy will be discussed in sections 1.8.3 and 1.9. 
 
1.6.3 Fibroblast growth factor (FGF)-family 
At the time of writing, 22 different proteins have been identified and classified as members of 
the FGF family139. Their biological effects are in general mediated by four different RTKs: 
FGFR1, FGFR2, FGFR3, and FGFR4. Interestingly, four members, the FGF-11, -12, -13, -14, 
are not signaling through these surface receptors, but rather have intracellular functions140. 
Furthermore, most FGFs are secreted from cells, however, certain members, including FGF-2, 
lack a secretory signaling peptide141. Release of FGF-2 is believed to occur through an 
endoplasmic-reticulum-independent mechanism (exocytosis), or from damaged cells142. The 
signaling axis of FGFs and their receptors are involved in multiple biological processes, 
  11 
including differentiation, proliferation, migration, and survival143, 144. In a broad sense, they are 
instrumental for the overall healthy organ development, but particularly in skeletal and vascular 
development145, 146. Global deletion models in mice reveal dramatically different outcomes 
dependent of which FGF-member that is removed. Some are viable with varying degrees of 
phenotypes, whereas others are embryonically lethal147. FGFs have also been implicated in 
development of diseases such as cancer148, Parkinson’s disease149, Alzheimer’s disease150, and 
skeletal diseases151. 
 
1.6.3.1 FGF-2 
FGF-2 has not only been identified to be a potent regulator of angiogenesis152, but also plays a 
role in lymphangiogenesis153, 154. FGF-2 induced angiogenesis has been reported to occur 
through both VEGF-A dependent and independent mechanisms155. Interestingly, FGF-2 
signaling leads to VEGF-A upregulation in ECs156-158. Mechanistically, FGF-2 is a pleiotropic 
factor acting on various cell types, such as ECs, PCs and VSMCs159, to regulate multiple 
processes including proliferation, migration, survival, and differentiation152, 160, 161. FGF-2 
signaling in VSMCs modulates contractility of the vessels and maintains the vascular tone. 
Consequently, FGF-2 is essential for regulation of blood pressure, inflammation, wound 
healing, metabolism, and bone formation161-163. Despite being involved in vital processes, mice 
with global deletion of FGF-2 are still viable and fertile. These mice only display moderate 
phenotypes, including reduced blood pressure, thrombocytosis, delayed wound healing, and 
neuronal defects161, 163. FGF-2 expression is induced in response to hypoxia164, but can also be 
regulated by factors such as PDGF-B165, EGF166, and TGF-β. FGF-2 is known to contribute 
to tumorigenesis and its expression has been detected both in tumor cells and stromal cells168, 
169. Furthermore, elevated levels of FGF-2 were detected in a wide range of cancer types170. 
Nevertheless, the clinical impact of FGF-2 expression is not clear. There are reports indicating 
significant correlation with poor prognosis in head and neck squamous cell carcinoma171, and 
oral squamous cell carcinoma patients172. In a study on breast cancer, the findings were 
opposite where patients with high levels of FGF-2 showed improved survival173. Moreover, 
survival in lung cancer patients appears to be dependent on the cellular source of FGF-2 as it 
was demonstrated that high tumor cell expression of FGF-2 correlated with poor prognosis, 
whereas opposite correlation was found if the FGF-2 was expressed in the stromal 
compartment174. Taken together, additional studies are required before conclusions of the 
tumor-contributing properties of FGF-2 can be drawn. 
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1.7 CYTOKINES 
Cytokines are small specialized secreted proteins classified according to their immune 
response-related effects. In general, cytokines are defined as being pleiotropic, i.e. the effect of 
one cytokine can be different depending on the target cell type. In addition, there is a 
redundancy in the system, meaning that different cytokines have overlapping functions175. 
There are several subgroups of cytokines, the; interleukins (ILs), interferons (IFNs), colony 
stimulating factors (CSFs), TGFs, TNFs, and chemokines176. Chemokines are characterized by 
having an effect on cell migration, as well as adhesion and activation177. Furthermore, cytokines 
can be grouped according to their pro- or anti-inflammatory effect; however, that can be context 
dependent as well. Four different classes of receptor proteins have been identified to be 
involved in cytokine signaling. These receptors are divided into type I cytokine receptors, type 
II cytokine receptors, TNF receptor family, and IL-1 receptor family178. Downstream signaling 
pathways of cytokine receptors include most of the common adaptor proteins such as ERK, 
Akt, p38, but frequently also NF-κB and JAK/STAT components for various biological 
outcomes179-181. The category of cytokines is comprised of a broad spectrum of proteins, and 
as one might expect, the processes where these are involved are equally diverse. Implication of 
cytokine signaling have be noted in the regulation of, for example, inflammation, infection, 
injury, body temperature, and psychological state including mood and appetite182-185.  
 
1.7.1 Interleukin (IL)-1 family 
The IL-1 superfamily of cytokines contains five identified members; IL-1, IL-18, IL-33, IL-36, 
and IL-37. The receptors for the IL-1 ligands are structurally similar and rely on similar 
principles for activation186. The intracellular domain, responsible for initiation of downstream 
signaling, is composed of a special Toll/IL-1R (TIR) domain187. In contrast to RTKs, most of 
these receptors do not form dimers among themselves, but rather depend on dimerization with 
an IL-1R accessory protein (IL-1RAcP) which also contains an intracellular TIR domain. Upon 
ligand binding, the receptor will interact with the IL-1RAcP leading to TIR domain 
dimerization, allowing for downstream signaling events to occur. Usually the intracellular 
signaling is conveyed through ERK, p38, or NF-κB leading to various biological outcomes, 
such as proliferation, migration, and production of cytokines, chemokines and tissue 
remodeling effector proteins176, 188, 189 (Figure 4). In addition to the involvement of biological 
processes previously described for cytokines in general, ILs can be drivers of pathological 
conditions, such as cancer190. Specifically, during diseases where chronic inflammation is an 
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underlying cause, including atherosclerosis191, Alzheimer’s disease192, and rheumatoid 
arthritis193, ILs commonly play an important role. 
 
 
Figure 4. Interleukin signaling pathways.  
 
1.7.1.1 IL-33 
IL-33 has been widely studied in various immunological settings as it was identified to be a 
potent regulator of the innate immunity as well as the adaptive T-cell response194, 195. Studies 
in both IL-33 and ST2 (IL-1RL1)-deficient mice revealed no obvious abnormal phenotypes 
under pathogen-free conditions and mice were fertile and developed normally. The mice do, 
however, have reduced immune reactivity and impaired production of certain cytokines194, 196, 
197. IL-33 is constitutively expressed in many different tissues198, 199, but typically is restricted 
to epithelial cells, fibroblasts and smooth muscle cells200. In humans, expression was first 
described in ECs201, 202, yet, such expression appears to be lacking in mice199, 203. Interestingly, 
in contrast to most other cytokines, IL-33 seems to be exclusively located in the nucleus195, 198, 
implying that IL-33 can act as a nuclear factor204, 205. Importantly, in line with the nuclear 
localization pattern and its constitutive expression, IL-33 has been recognized as an alarming 
cytokine signaling upon tissue damage or as a result of necrotic cell death205, 206. Cellular stress 
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or injury would, hence, lead to the extracellular release of IL-33, functioning as an alarm signal 
and trigger an immune response. This process does not occur during apoptosis as active 
caspases would cleave IL-33 to become inactive207. Recent findings have, however, reported 
that living cells also actively can secrete IL-33208, 209. Extracellular biological activity is 
mediated by binding to the ST2 receptor present on many immune cells, including 
macrophages210, 211, mast cells212, and CD4+ T-cells213. IL-33 has been demonstrated to be 
involved in cellular differentiation, activation, adhesion, proliferation, and cytokine production 
in its target cells214. Pro-inflammatory cytokines, such as TNF-α and IFN-, in turn, potently 
regulate IL-33 expression212. Implication of IL-33 in pathology includes cancer, asthma and 
rheumatoid arthritis215, 216. Regarding the role of IL-33 signaling in cancer, results from pre-
clinical models are pointing towards different directions. There are several tumor studies 
performed in mice that indicate a pro-tumorigenic effect of IL-33 on tumor progression, 
invasion and metastasis in breast cancer217, ovarian cancer218, gastric cancer219, and colorectal 
cancer220, 221. In contrast, opposing results were recently published by others using mouse 
models of breast cancer and melanoma222, as well as colon cancer223. In one of these studies, 
the anti-tumorigenic effects were probably due to an increased number of cytotoxic T-cells and 
natural killer cells222. In cancer patients, the findings are reflecting the pro-tumorigenic effects 
of IL-33 and strong associations between high IL-33 expression and poor prognosis have been 
reported in ovarian cancer218, glioma224, and squamous cell carcinoma of the tongue225. 
 
1.8 THE METASTATIC CASCADE AND INVOLVEMENT OF THE TUMOR 
MICROENVIRONMENT  
The involvement of tumor microenvironment in initiation, progression and spreading of tumors 
has been well recognized during the past years and was introduced as an important key 
compartment in the updated version of hallmarks of cancer in 20116. It is known that an 
extensive dynamic communication occurs within tumors; between tumor cells, vascular cells, 
perivascular cells, and fibroblasts, as well as immune cells. In fact, the tumor cells are not only 
able to escape the regulatory systems, but also induce an active signaling to produce a favorable 
environment. Under those signals, tumor cells educate the body’s own cells to use their 
functions for tumor-promoting advantages226. This interplay is of crucial importance for 
providing immune escape, treatment resistance mechanisms, and facilitating tumor 
spreading227. Microenvironmental opportunities for cancer therapy will be discussed in the 
following sections. 
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1.8.1 The metastatic process 
Despite being an inefficient process where tumor cells either do not survive in the circulation 
or fail to establish a metastatic colony228, metastatic spread is very common and in fact 
responsible for around 90% of cancer-related deaths229. These numbers justify the prominent 
role of acquiring an invasive phenotype as one of the hallmarks of cancer. There are several 
important and challenging steps that occur during the process of metastatic dissemination and 
eventually lead to successful colonization230 (summarized in Figure 5).  
 
 
Figure 5. A simplified overview of the metastatic process. 
 
In brief, cellular changes occur within the primary tumor to generate tumor cells with more 
invasive characteristics that are able to break loose, invade locally, and migrate towards the 
blood and lymphatic vessels. The cells then need to intravasate into the vascular system. As 
previously discussed, the environment in the circulation, especially the blood system, is 
mechanically harsh but there are also plenty of immune cells posing a threat to the tumor cells. 
The tumor cells struggle to survive such stressful conditions. Tumor cells are usually arrested 
in capillaries at the site of a distant organ, commonly lungs and liver. Here, the tumor cells 
must extravasate in order to form metastatic colonies. Subsequent metastatic growth is 
dependent on several aspects. In fact, if the environment is unfavorable, tumor cells have been 
found to remain in a dormant stage for years before regrowth is initiated and metastases can be 
clinically detectable231. 
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The complex process of metastatic dissemination can be influenced at many levels and by many 
different factors. As in most steps in tumor progression, the microenvironment has been found 
to play instrumental roles in the metastatic process232. This can be exemplified by hypoxia, 
which is commonly found in the growing tumor and is known to be one of the major inducers 
of metastasis-related genes233, 234. Under normoxic conditions, the HIF-1α, a transcription 
factor, is targeted for degradation. This process is dependent on hydroxylation of the HIF-1α 
protein by a group of enzymes known as prolyl hydroxylases (PHDs). When there is a lack of 
oxygen, these PDHs are not active and hence, HIF-1α can be accumulated and translocated to 
the nucleus where it will regulate transcription of its target genes235. Importantly, hypoxia 
affects all cells in the tumor tissue. Again, there is an effect on the stromal compartment by 
factors produced under hypoxic conditions to recruit cells and engage them in the metastatic 
process to facilitate dissemination. For example, certain immune cells, including macrophages 
(Mφ) and neutrophils that can be recruited to boost tumor cell proliferation and promote 
invasion by different mechanisms236, 237. Clinically, it has been reported that expression of HIF-
1and HIF-2 correlates to poor prognosis in various tumor types, for instance in late stage breast 
cancer238, colorectal cancer239, and metastatic renal cancer240. Collectively, these findings 
further confirm the role of direct and indirect regulation by hypoxia in the tumor progression 
and metastasis. 
 
1.8.1.1 Local invasion 
Prior to understanding the process of local invasion, it is central to understand the fundamental 
structures and cell behaviors of tissues. Importantly, as tumor cells in the primary tumor are 
frequently (approx. 90%) of epithelial origin241, the cells are well organized and have a specific 
polarization with apical (luminal), lateral, and basal sides. On the basal side of the cell layer, 
cells are anchored to the basement membrane via, for example, integrins. On the lateral sides 
between epithelial cells, there are several different categories of junctions, such as tight 
junctions, adherens junctions, and desmosomes that provide strong cell-cell adhesions242. All 
these aforementioned features are limiting cell migration. During tumor progression, tumor 
cells are gaining various advantages by gene mutations or regulation of gene expression. In 
context of primary tumor invasion, the cells need to detach from neighboring cells. A cell can 
accomplish that by different means. One such process known to occur; is epithelial-to-
mesenchymal transition (EMT)243. Probably the most well-studied factor in the context of EMT 
is TGF-β. Signaling through the TGF-β type I and II receptors, activates Smad2/3 
downstream effector proteins and eventually initiates several important signaling events. In the 
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frame of reference of EMT, TGF-β signaling will, for example, lead to the loss of E-cadherin, 
the receptor that forms adherens junctions. As a consequence of this event, -catenin, a 
transcription factor that is associated to E-cadherin, will be released and relocate to the nucleus 
where it can upregulate various genes involved in proliferation, survival, and differentiation. 
Collectively, the process of EMT leads to increased migratory capacity and reduced cell-cell 
junctions. Together, these downstream events of TGF-β signaling are sufficient to induce the 
EMT program and allow cells with an acquired mesenchymal phenotype to detach245, 246.  
 
1.8.1.2 Intravasation 
Following acquisition of migratory and invasive phenotypes, tumor cells are facing another 
rate-limiting step, the intravasation process. Entry into the blood system seems to require more 
advanced steps compared to entry into the lymphatic system, for reasons discussed in sections 
1.3 and 1.5. The approaches by which tumor cells are crossing the endothelial barrier can be 
different. Two modes of intravasation by transmigration; paracellular (between ECs) and 
transcellular (through ECs), have been proposed to be utilized by tumor cells247. Paracellular 
transmigration is believed to be the most common mechanism in vivo. The molecular details 
underlying this process are not fully understood, however, it has been shown that matrix 
metalloproteinases (MMPs) are involved. One report identified a regulation of endothelial 
permeability by MMP-1 via activation of the protease-activated receptor-1 expressed on ECs, 
leading to increased tumor cell intravasation248. Importantly, for tumor cells to gain access to 
the circulation, the ECM and basement membrane act as a protective barrier that needs to be 
degraded. Various MMPs and other proteases, which can be both tumor cell-derived or 
produced by non-malignant cells such as Mφ, are responsible for degrading different 
components of these structures249. Blocking of, for example, MMP-9 in pre-clinical models has 
been shown to lead to significantly impaired metastatic capacity250, 251. 
 
1.8.1.3 Extravasation 
Tumor cells that are able to survive in the blood circulatory system have a new challenging 
step to complete, the process of extravasation, before they have gained access to the distal 
organ. In regards to the immune system, extravasation is the manner by which leukocytes enter 
tissues. Tumor cells are believed to utilize the same steps of extravasation, i.e. rolling, adhesion, 
and transmigration252. The underlying mechanisms are not yet well characterized in the case of 
tumors. There are studies indicating a role for integrins as the means by which tumor cells are 
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capable to attach to the endothelium and subsequently transmigrate253. Specifically, integrin β1 
has been identified as a mediator of extravasation254 and has been shown to be associated with 
poor prognosis in various type of cancer types, including lung cancer255, breast cancer256, and 
metastatic melanoma257. Interestingly, in a pre-clinical model, tumor cells were recently found 
to promote their extravasation by inducing necroptosis (a form of programmed cell-death) in 
ECs to gain access to lung tissues. This process was shown to be mediated by death-receptor 6 
activation258. In addition, transmigration can be facilitated by enhancing vascular permeability, 
which can be accomplished by secretion of factors such as VEGF-A259, TGF-β, or 
angiopoietin-like-4261. After successfully completing this difficult step-wise process, the tumor 
cells have the opportunity to form an established metastatic colony.  
Non-malignant cells have been identified to be critical in the overall metastatic process. As the 
central focus of the current study, was to investigate the mechanisms of tumor 
microenvironment in promoting metastasis, the roles of ECs, PCs, and Mφ will be discussed 
in the following sections in relation to metastasis and potential targeted therapy. Although the 
contributions of tumor-associated fibroblasts are being well recognized in tumor development 
and progression, the topic is outside to scope of our findings, and hence will not be discussed 
in detail. 
 
1.8.2 Endothelial cells (ECs) 
Blood vessels are a crucial part of the architecture within a tumor and, as detailed earlier, 
provides a common route for dissemination. As the main role of the blood system is to deliver 
oxygen, the vessels are in that sense also regulating tissue hypoxia, which is known to affect 
various aspects of tumor progression, as previously discussed in section 1.8.1. Even in a healthy 
tissue, the ECs are important for maintaining tissue homeostasis and regulating tissue 
inflammation by, for example, controlling the transmigration of immune cells262. In addition to 
the previously mentioned, obvious vessel-related functions, the ECs have been found to make 
further contributions. In fact, recent findings indicate a link to direct tumor-promoting effects 
on proliferation and invasion exerted by EC-derived factors263. Also, tumor cell-EC 
communication has been reported to render ECs resistant to a number of chemotherapeutic 
agents by acquiring expression of anti-apoptotic proteins. As a result, the tumor vasculature 
can remain even after treatment and continue to support surviving tumor cells, again 
contributing to resistance264.  
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When looking at the blood vasculature as a target for treatment, the initial strategy and idea 
was to starve the tumor. Killing of ECs would lead to reduced tumor vascularity, consequently 
less oxygen and nutrients will reach the tissue and increase the chance of apoptosis and tumor 
regression265. Early experimental data was in support of this hypothesis and blockade of VEGF-
A signaling in pre-clinical models proved to be successful in a range of different tumor 
models266. These findings led to the development of a first anti-VEGF-A neutralizing antibody, 
Bevacizumab (Genentech)267. Clinically, the results have been less beneficial and researcher 
are still attempting to understand the mechanisms. However, Bevacizumab is currently 
approved by the Food and Drug Administration (FDA) for treatment of various tumor types, 
in general, at an advanced metastatic or recurrent stage. Importantly, the approval is based on 
combination treatment with chemotherapeutics. Despite a promising initial hypothesis, 
emerging evidence is, however, suggesting that induction of hypoxic conditions might not be 
that beneficial. Reports are instead proposing a strategy leading to improved blood perfusion 
and alleviated hypoxia. This would be preferred, especially in combinational settings, since it 
has been shown to increase delivery of a secondary drug, commonly a chemotherapeutic 
agent265. Additional efforts are ongoing. The second and third generations of anti-angiogenic 
agents, such as the tyrosine kinase inhibitors sorafenib (Bayer) and sunitinib (Pfizer), are now 
available for clinical use. The key question is how to select the right treatment for individual 
patients.  
 
1.8.3 Pericytes (PCs) 
The tumor-regulating functions of PCs are still being debated. As PCs are covering the outside 
of the capillary blood vessels to provide support, they also constitute an effective barrier to 
prevent intravasation of cells and hence are, in that context, believed to limit the metastatic 
potential of a tumor268. One report indicated a strong correlation between low perivascular 
coverage and poor prognosis in clinical samples from breast cancer patients269. It is, however, 
important to realize that the tumor vasculature is highly heterogeneous with different levels of 
coverage in different areas, which may affect treatment outcome270. We and others have shown 
how PCs can actively participate to promote metastasis by different mechanisms. On one hand, 
PCs have been found to undergo transition into tumor-associated fibroblasts and contribute to 
metastasis271. Additionally, we identified PCs as a source of IL-33, which was reported to 
promote metastasis by modulating the immune cell compartment221, 272. The therapeutic setting 
can be exemplified by imatinib (Novartis), a small molecule, which is approved as first-line 
treatment of KIT+ gastrointestinal stromal tumors273. Imatinib has several targets, including 
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PDGFRs, and is reported to modulate the vascular coverage by ablating PCs274. This 
consequently renders ECs more susceptible for combination treatment with, for example, anti-
VEGF-targeting agents. Such combinations have shown promising results in various pre-
clinical models275, 276. However, one recent clinical study on combination therapy in melanoma 
failed to observe any clinical benefits277.  
Available literature is not only focused on if there is a therapeutic effect of targeting PCs in 
tumors, or not. But also, caution is to be taken, as it has been reported that targeting PCs can 
also increase the risk for metastasis. Interestingly, targeting PCs at early stages in tumors or 
when the level of PDGF-BB is high seem to reduce tumor progression and inhibit 
dissemination. In contrast, in late stage tumors or if levels of PDGF-BB are low, metastasis 
was promoted in settings where PCs were targeted278, 279. In light of these reports, it is 
noteworthy to mention that, in the clinical setting, cancer is usually detected at a later stage, 
possibly reducing the potential success of this approach. In contrast to this strategy, some 
results are suggesting that attempts should be made to stabilize the EC-PC interactions to 
increase the PC coverage, which could be accomplished by antagonizing the Ang-2 
signaling280. Trebananib (Amgen), a peptibody blocking both Ang-1 and -2 interaction with 
Tie-2, was reported to increase progression-free survival in recurrent ovarian cancer patients 
when combined with paclitaxel compared to paclitaxel alone281. A more specific antibody, 
Nesvacumab (Regeneron), which is only neutralizing Ang-2, is showing promising anti-
tumorigenic effects in early clinical trials282.  
 
1.8.4 Macrophages (Mφ) 
The components of the immune system protect the body against danger and potential diseases. 
Tumor cells are, however, to a large extent capable of evading the immune surveillance and 
persist283. As is true for other cellular compartments, tumor cells are able to modulate the 
phenotypes of immune cells. Immune cells are intrinsically dynamic and their functions and 
polarization can be changed according to the environmental need284. One population of 
immune cells found in abundance in tumor tissues is Mφ. Macrophages can be tissue-resident 
or recruited from the periphery and they play an important role in host defense both by direct 
phagocytosis of microbes and activation of T- and B-lymphocytes285, 286. Depending on the 
circumstances, Mφ can become “classically activated” to generate M1 type, which is pro-
inflammatory, or “alternatively activated” to become anti-inflammatory M2 type287. In the 
context of tumor studies, the M1 subtype has been identified to be anti-tumorigenic by e.g. 
stimulating the immune response. In contrast, the M2 subtype has been found to act in favor of 
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the tumor by engaging in various processes. For example, these cells are producing anti-
inflammatory cytokines to dampen the immune response288. In addition, they are an important 
source of matrix degrading proteins that facilitates tumor cell invasion, but also contribute to 
resistance by producing pro-angiogenic factors289. Moreover, Mφ have been shown to play an 
even more active role in the metastatic process by guiding and helping tumor cells to 
intravasate290, 291. At least in part, this Mφ-tumor cell communication was shown to involve 
CSF-1R292, 293. Collectively, there is clear evidence for Mφ being an important contributor to 
tumor progression.  
Recently, growing interest in the population of Mφ as an attractive target for therapy has led to 
development of CSF-1R neutralizing antibodies and small molecules. The mechanisms behind 
the potential success of such approach are still under investigation, some reports indicate a 
process of re-programming upon treatment294, whereas others point towards induction of cell 
death295. Of note, a recent publication described an increase in spontaneous metastatic potential 
when neutralizing CSF-1R in a breast cancer model, indicating that caution might be needed296. 
Additional studies are required before final conclusions can be drawn on the future of CSF-1R 
targeting agents. Interestingly, a different Mφ-targeted approach, taking advantage of the 
fundamental characteristics of this cellular population of being an effective contributor to cell 
and pathogen destruction, is based on CD40 activation. CD40 is expressed on many cell types 
and was found to activate Mφ leading to IFN--mediated tumor cell killing297. Based on that 
notion, agonistic CD40 antibodies have been developed. One such antibody, CP-870,893 
(Pfizer), is currently in clinical trials298, 299 after displaying promising anti-tumorigenic activity 
in mouse models300. 
 
1.9 TREATMENT OF CANCER PATIENTS 
From the evolvement of modern cancer surgery in the 19th century, radiotherapy in early 20th 
century, and chemotherapy in the middle of the same decade, today’s cancer therapy has come 
a long way. The realization that tumors are able to regrow or become resistant when applying 
these therapeutic interventions301, 302, contributed to continuous effort being put on finding new 
strategies for cancer treatment. Along with great progress in tumor detection using computed 
tomography and introduction of detection and screening processes, several different types of 
treatments were developed, including improved chemotherapeutics, hormonal therapy for 
breast and prostate cancer patients, vaccination for colon and cervical cancer, and new 
radiotherapy techniques. Tumors, however, often respond poorly to many of these available 
drugs303.  
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In recent years, interesting progress in the field of targeted therapies has improved the 
opportunities for individual treatment and increased overall survival in many types of cancer. 
Although the already established tamoxifen treatment is regarded as a targeted therapy by its 
binding to the estrogen receptor and blocking its interaction with estrogen, the first antibody-
based drug designed for a molecular target in cancer, rituximab (IDEC Pharmaceuticals), 
received a lot of attention and initiated the field of targeted therapy. In 1997 it became the first 
drug ever of its kind to get approval by the FDA, the indication was treatment of Non-
Hodgkin’s lymphoma (NHL). Rituximab is a monoclonal antibody targeting the CD20 antigen 
expressed on B-cells, which is the most common malignant cell type in NHL304. Following this 
approval, additional tumor cell-targeting antibodies were approved, such as trastuzumab 
(target; HER2, Genentech) in breast cancer, and cetuximab (target; EGFR, ImClone Systems) 
in colon cancer. Not only antibody-based approaches have been developed, small molecules 
are an attractive alternative due to their chemical stability, potency, and less immune-reactive 
properties along with being more cost-effective305. FDA-approved small molecules includes 
imatinib (target; Bcr-Abl, c-Kit and PDGFRs, Novartis) in chronic myeloid leukemia (CML), 
and gefitinib (target; EGFR, AstraZeneca) in lung cancer.  
All these aforementioned therapies are based on targeting tumor cells, and are commonly 
facing the problem of resistance in the clinical setting. As discussed in previous sections, the 
different compartments of the tumor microenvironment have been identified to influence all 
the steps of tumor progression, including metastasis and resistance306-308. Despite the layer of 
complexity of microenvironmental interactions, it provides an attractive opportunity for 
therapeutic interventions. In fact, looking at clinical trials and already FDA-approved drugs, 
there are targets for different compartments in the tumor microenvironment. One of those 
attractive targets are the immune cells with the overall aim to amplify the anti-tumorigenic 
effects of the immune system. Such approaches are employed by drugs targeting proteins 
expressed on T-cells (CTLA-4 and PD-1), or macrophages (CD40 and CSF-1R). Some 
examples are: ipilimumab (target; CTLA-4, Bristol-Myers Squibb), nivolumab (target; PD-1, 
Bristol-Myers Squibb), CP-870,893 (target; CD40, Pfizer), and AMG-820 (target; CSF-1R, 
Amgen). Furthermore, several drugs have been generated to modulate vascular and 
perivascular cells by targeting VEGFRs, PDGFRs, or the Ang system. Some examples are: 
bevacizumab (target; VEGF-A, Genentech/Roche), aflibercept (target: VEGF-A, VEGF-B, 
and PlGF, Regeneron), sunitinib (target; VEGFRs and PDGFRs, Flt3, and CSF-1R, Pfizer), 
imatinib (target; Bcr-Abl, c-Kit and PDGFRs, Novartis), sorafenib (target; VEGFRs, PDGFRs, 
Raf, and Kit, Bayer), pazopanib (target; VEGFRs, PDGFRs, Kit, GlaxoSmith Kline), AMG-
386 (target; Ang-2, Amgen), trebananib (target; Ang-1 and Ang-2, Amgen), and nesvacumab 
  23 
(target; Ang-2, Regeneron). These drugs have generated promising pre-clinical data and 
showed potential in clinical trials in combination with other anti-cancer therapies. However, 
the anti-angiogenic drugs, so far, to reach the clinic have only limited efficacy309. Pre-clinical 
data from a study using VEGFR inhibitor in a mouse pancreatic tumor model, demonstrated 
that anti-angiogenic targeting in late-stage tumors, a point where patients usually come to the 
clinic, had limited effect compared to early treatment. It was concluded that VEGFR blockade 
was inefficient in regressing tumors with pre-established vascular network. Furthermore, this 
study indicated that combination therapy where VEGFR and PDGFR are targeted 
concomitantly, yielded superior anti-tumorigenic properties, even in late-stage tumors275.  
As is true for most treatment options today, drug resistance is one of the major hurdles. In the 
frame of references of anti-angiogenic therapy, there are many hypotheses to how tumors are 
becoming resistant. Again, the microenvironment seems to play an important role in the 
contribution to resistance. Upon anti-angiogenic therapy, some tumor vessels will regress, 
leading to a hypoxic environment. On one hand, hypoxic tumor cells are resistant to 
chemotherapy and radiotherapy310, 311, and there is a selection of cells that do survive, for 
example those insensitive to apoptosis and thereby not responsive to drugs with apoptosis-
dependent mechanisms311. On the other hand, as mentioned in an earlier section, hypoxia is 
regulating a wide range of processes by controlling gene expression in basically all cells within 
the tumor. Many of those processes are involved in escape from cell death. These issues are 
challenging, but there is intriguing research ongoing in the field of targeting hypoxia in tumors 
to improve the efficacy of secondary drugs312. 
Taken together, drugs targeting the microenvironment can be successful when applied in 
appropriate settings. It is crucial to gain further understanding of the intratumoral 
communication that has been proven to limit the therapeutic effects, and to apply the right 
combinations of drugs, in the right settings to achieve improved treatment of cancer patients.  
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2 AIMS 
The overall aim of this thesis was to study the influence of tumor microenvironment in the 
process of metastasis and to investigate current cancer therapy. 
 
More specifically, the aims were: 
I. To explore the role of PDGF-BB in the tumor microenvironment 
II. To investigate the mechanisms behind PDGF-targeting therapy in cancer  
III. To study the influence of VEGF-B in context of tumor metastasis 
IV. To investigate lymphangiogenesis and potential interplay of two common 
lymphangiogenic factors; VEGF-C and FGF-2
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3 RESULTS 
The constituent papers in this thesis work describe different mechanisms employed by 
various cellular compartments in regulating the metastatic process. We report how 
modulation of angiogenesis (paper I, and III) and lymphangiogenesis (paper IV) influence 
the metastatic potential of tumors. In addition, we identify mechanisms underlying the pro-
metastatic contributions of PCs (papers I, and II) and Mφ (papers II, and III) in the tumor 
microenvironment. 
3.1 PAPER I 
PDGF-BB expression serves as a biomarker for anti-PDGF therapy by influencing the 
vascular remodeling and having an impact on tumor metastasis   
PDGF-BB is a known mitogen that contributes to tumor growth, and plays an instrumental 
role in PCs recruitment to vessels. Despite several studies in pre-clinical and clinical settings, 
the role and mechanisms of PDGF-BB-modulated tumor vasculature remains largely unclear. 
Understanding the role of PDGF-BB in cancer is motivated by the frequent expression of 
PDGF-BB in tumors, which has been noted in various types of tumors313. The fact that anti-
PDGF drugs are currently a part of clinical practice for targeting of PDGF signaling in 
tumors, justifies further investigations on the underlying mechanisms to guide appropriate 
use of anti-PDGF targeting. We and others previously identified how PDGF signaling is 
essential for vascular remodeling, however, overexpression of PDGF-BB has been found to 
increase metastasis in pre-clinical models. In this study, we wanted to understand the 
mechanisms of PDGF-BB effects on the vascular phenotype and impact on metastasis in 
tumors, as well as clarify the impact of anti-PDGF targeting. 
To address the role of PDGF-BB in tumors, we employed human tumor xenografts in mice. 
A human epidermoid cancer cell line (A431) was selected for its high expression, and a 
neuroblastoma cell line (IMR32) displayed relatively low PDGF-BB expression. Vascular 
analysis of these tumors, revealed significant differences in the perivascular coverage. 
Interestingly, despite the role of recruiting PCs to the vasculature, the high PDGF-BB 
expressing A431 tumors showed less coverage and reduced total number of PCs. To validate 
that PDGF-BB was playing a role in the vascular phenotype, we propagated murine tumor 
models to overexpress PDGF-BB at different levels. In these models, we were able to 
reproduce the findings observed in the human tumor models. We could also confirm that 
vascular disorganization was increased as the level of PDGF-BB increased. 
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To elucidate the effects of anti-PDGF drugs in settings where expression of PDGF-BB is 
different, we treated the human and mouse tumors with a neutralizing PDGFR-β antibody or 
imatinib. From these experiments, it was evident that the tumors responded unexpectedly 
different. In line with the suggested mechanism of such drugs, the vascular coverage was 
significantly decreased in tumors with low PDGF-BB levels. In contrast, to our surprise, 
blockade in tumors with high expression of PDGF-BB, displayed improved vascular 
coverage. Further analyses of the vascular qualities by injection of low molecular weight 
dextran (70kDa) indicated that the high vascular leakage observed in PDGF-BB high tumors, 
was significantly reduced upon anti-PDGF treatment. Here, again, opposing results were 
detected in tumors with low PDGF-BB expression. 
As the degree of vascular coverage and permeability are possibly related to the feasibility of 
intravasation, we wanted to study the metastatic outcome. Detection of circulating tumor 
cells (CTCs) after treatment with imatinib, showed that dissemination was inhibited in A431 
tumors, hence when PDGF-BB is high. Inversely, IMR32 tumors had a trend of increased 
CTCs. These findings where reproduced in the murine tumor model, where CTCs, in 
addition, were also found to be correlated to pulmonary metastasis. 
To further understand how PDGF-BB is regulating PCs in the tumor, we conducted several 
in vitro studies using isolated PCs. Interestingly, persistent stimulation with high doses of 
PDGF-BB leads to downregulation of surface-available PDGFR-β by promoting 
internalization. In line with these in vitro studies, levels of PDGFR-β in tumor tissues exposed 
to high PDGF-BB expression were downregulated. By performing a gene array of PDGF-BB 
stimulated PCs and comparing to non-stimulated control PCs, we identified a wide range of 
genes with differential expression. We chose to focus on genes involved in EC-PC 
interaction, and identified integrin α1 as being the most downregulated adhesion molecule. 
To generate a functional adhesion molecule, integrin α1 combines with integrin β1, both of 
which were confirmed by qPCR to be downregulated upon PDGF-BB stimulation. These 
results indicate that loss of α1β1-binding is a consequences of prolonged PDGF-BB 
stimulation and PDGFR-β downregulation. Subsequent experiments with treatment of 
tumors with α1β1 neutralizing antibodies could successfully reproduce the loss of PCs 
observed in PDGF-BB high tumors. Collectively, this data demonstrates that high doses of 
tumor cell-derived PDGF-BB, at least in part, leads to reduced vascular coverage by 
downregulation of integrin α1β1-dependent EC-PC interaction. This destabilization does not 
occur during angiogenesis when ECs are the main source, probably due to the relatively low 
production of PDGF-BB.  
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In summary, we report that PDGF-BB expression levels strongly determine the treatment 
outcome when using anti-PDGF drugs, and that treatment may potentially promote 
metastasis. Furthermore, we identify the underlying mechanisms of PDGF-BB-induced 
vascular remodeling in tumors. In addition, we found that PDGF-BB may serve as a 
biomarker for selection of patients for anti-PDGF therapy. 
 
3.2 PAPER II 
PDGF-BB is inducing an IL-33-dependent communication between perivascular 
stromal cells and macrophages leading to a metastasis-promoting microenvironment 
When analyzing tumor tissues from PDGF-BB overexpressing tumors, we noted that the 
population of Mφ where drastically increased in numbers. Interestingly, Mφ are not directly 
responsive to PDGF-BB stimulation as they lack PDGFR expression, indicating a potential 
role for an indirect mechanism. In this study, we set out to investigate how PDGF-BB is able 
to trigger an increase in Mφ. Additionally, as Mφ have been demonstrated to be important in 
tumor cell dissemination, we wanted to explore any potential impact on metastasis in our 
tumor settings. 
For initial studies, we chose to use the previously identified high PDGF-BB expressing 
human tumor cell line, A431. As a control, shRNA was used to downregulate the PDGF-BB 
levels. By performing immunohistochemical staining and FACS analyses of such tumors, we 
could conclude that Mφ were effectively reduced when PDGF-BB was downregulated. To 
confirm the role of PDGF-BB we used two established murine tumor cell lines with stable 
PDGF-BB overexpression. Here, we detected significant increases in PDGF-BB high tumors 
compared to vector-only transfected tumors, further confirming the contributions of PDGF-
BB. In an effort to point-out which receptor that was responsible, we treated tumors with 
imatinib (blocks both PDGFR-α and -β), a specific anti-PDGFR-α, or an anti-PDGFR-β 
neutralizing antibody. Imatinib and PDGFR-β blockades were able to inhibit PDGF-BB-
induced Mφ infiltration, whereas PDGFR-α failed to do so. Co-localization experiments 
demonstrated that Mφ in the murine tumor model lacks PDGFR expression. As it is known 
that the main cellular target of PDGF-BB is PCs, we focused on this cell type.  
The effects of PDGF-BB on PCs, in addition to the main role of recruitment onto vessels, is 
not known. By performing a gene array of PDGF-BB stimulated PCs and comparing to non-
stimulated control PCs, we were able to identify potential mediators of PDGF-BB-induced 
Mφ infiltration. Among all genes, IL-33 was the most upregulated and known to regulate 
 28 
various immune cells and, hence, was selected for subsequent studies. Analyses of IL-33 
protein and mRNA levels in PDGF-BB tumors validated PDGF-BB-driven increase in IL-33 
expression. Specifically, detailed analysis identified PDGFR-β-positive cells, including PCs, 
to be the main source of IL-33. Previously, PDGFR-β was identified in vivo for Mφ 
infiltration. To verify if PCs are producing IL-33 in response to PDGFR-β activation, we 
performed blockade experiment in vitro and could conclude the involvement of PDGFR-β, 
whereas PDGFR-α not seemed to be involved. The underlying molecular mechanisms of 
PDGF-BB-induced upregulation of IL-33 was previously unidentified. In vitro experiments 
and array analysis of PDGF-BB-stimulated PCs revealed that Sox7, a transcription factor, is 
mediating the transcriptional regulation of IL-33 by binding to SRY-boxes in the promoter 
region. 
So far, IL-33 has been identified as a potential link between PDGF-BB and Mφ infiltration. 
To investigate the effect of IL-33 on Mφ, we performed in vitro studies using a murine Mφ-
like cell line. As IL-33 is known to signal through its receptor ST2, we first confirmed that 
our cell line expressed this receptor by FACS and RT-PCR. IL-33 potently induced activation 
of ERK, p38, and NFκB pathways in these cells. Upon IL-33 stimulation, increased migratory 
capacity along with activated morphological changes could be detected. Together with 
induction of several M2-related genes, including CD206, these results are confirming the 
ability of IL-33 to activate and polarize Mφ. 
In tumor settings, the role of IL-33 remains largely unknown, but has been well studied for 
its role in modulating the immune system. Here, we used a murine pancreatic tumor cell line, 
Panc02, selected because of its high expression of IL-33 in tumor tissue. In addition, we 
generated murine tumor cells with stable expression of IL-33. In this gain-of-function tumor 
model, we detected an increase in Mφ infiltration. Notably, no significant effect on tumor 
growth was observed, probably indicating a direct tumor-promoting effect of PDGF-BB in 
those tumors, independent of IL-33. IL-33 effects on the Mφ population was further 
confirmed in loss-of-function models by implanting Panc02 tumors in mice lacking IL-33 or 
ST2 gene expression, or treating with soluble ST2 protein (acting as a decoy receptor). In 
these models, Mφ infiltration was significantly impaired. Similar results could be reproduced 
by using PDGF-BB expressing tumors in the same models, further strengthening the link 
between PDGF-BB and IL-33. 
The field of tumor immunology is boosting, especially tumor-associated Mφ are popular to 
study in tumors. Mφ are plastic and depending on the environment, different subtypes can be 
induced, and we wanted to investigate the effects of IL-33. By performing array, qPCR, and 
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FACS analyses, along with immunohistochemical staining of independent markers, we could 
conclude that IL-33 is a potent inducer of Mφ polarization towards M2, which has been 
shown to be the tumor-promoting subtype.  
Furthermore, as we previously found that PDGF-BB expressing tumor show increased 
metastatic capacities, we wanted to explore the IL-33 potential in relation to metastasis. 
Using subcutaneous and liver implantation models, it became evident that IL-33 is driving 
tumor cell dissemination, concluded from CTC detection, as well as metastatic growth as we 
detected increased pulmonary metastasis. Depletion of Mφ with clodronate liposome 
treatment, significantly impaired the metastatic potential of IL-33-driven tumors, including 
the gain-of-function overexpressing tumors, as well as Panc02 tumors. 
In summary, we provide detailed information of PDGF-BB-induced metastasis in tumors by 
a previously unknown mechanism. We identify the common inflammatory cytokine, IL-33, 
as being responsible for promoting the Mφ infiltration seen in PDGF-BB expressing tumors. 
Furthermore, we confirm that this population of Mφ are the critical mediators of metastasis. 
In light of these findings, new strategies, including IL-33 blockade and Mφ targeting, for 
therapeutic interventions can be developed to prevent tumor metastasis. 
 
3.3 PAPER III 
Identification of VEGF-B as a marker of poor prognosis by modulating the tumor 
microenvironment and promoting metastasis 
Tumor angiogenesis and vascular remodeling are important processes for tumor development 
and progression314. There are many potent regulators of the vasculature found to be expressed 
in tumors. Here, we focused on one of the VEGF-family members, VEGF-B. Whereas 
VEGF-A-driven angiogenesis has been widely studied, the VEGFR1-only binding ligands, 
especially VEGF-B, remains less characterized. Early reports on the pro-angiogenic activity 
of VEGF-B has not been able to be reproduced, and its dependence on VEGF-A is debated. 
This promoted us to engage in a thorough study to investigate the role of VEGF-B in a tumor 
setting. 
As VEGF-B expression has been detected in various human tumors, we selected 28 different 
human tumor cell line to screen for VEGF-B expression. From this experiment, we identified 
two human melanoma cell lines with differential expression, the MDA-MB-435 was among 
the highest, and UACC-62 expressed relatively low amounts. To generate appropriate 
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controls, we used specific shRNA to downregulate VEGF-B expression in MDA-MB-435, 
while we propagated UACC-62 to overexpress VEGF-B. 
Loss-of-function experiments were performed by implantation of the two MDA-MB-435 cell 
lines in mice. Notably, loss of VEGF-B expression had no impact on primary tumor growth. 
Examination of the vascular phenotype in these tumors, revealed a significant increase in 
vessel density and disorganization in the shRNA-tumors compared to endogenously high 
VEGF-B expressing tumors. In correlation to these findings, the vasculature displayed 
improved perfusion and decreased permeability. As a consequence, tumors showed reduced 
level of tissue hypoxia. Interestingly, we also detected a decrease in the number of tumor-
associated Mφ, as determined by CD206 (M2 marker) and F4/80 (pan-marker) co-staining, 
in VEGF-B-downregulated tumors. Collectively, these results indicate that VEGF-B is able 
to significantly modulate the tumor microenvironment, function as a negative regulator of 
angiogenesis, and have pronounced effect on the vasculature. 
Next, we studied the effect on VEGF-B in an independent, gain-of-function model, where 
we implanted control and VEGF-B overexpressing UACC-62 cells in mice. Introduction of 
VEGF-B expression in this tumor model, in contrast to the loss-of-function model, led to 
reduced tumor growth. Furthermore, VEGF-B tumors displayed decreased vascular density 
with fewer branch-points. Despite this normalized appearance, pericytes coverage was poor, 
and endothelial cell junctions, as determined by VE-cadherin staining, were impaired. 
Consequently, the vasculature was leaky and poorly perfused, showing increase level of 
hypoxia. In addition, VEGF-B significantly increased the number of tumor-associated Mφ. 
For confirmation purposes, we generated a murine tumor cells to stably express VEGF-B 
using fibrosarcoma cell line, T241, with no significant endogenous VEGF-B expression. This 
model was able to reproduce the findings detected in the human tumor models. These results 
suggest that VEGF-B is inhibiting tumor growth and angiogenesis, along with displaying 
vascular remodeling properties rendering tumors hypoxic, and contributing to increased 
numbers of Mφ infiltration. 
The vascular phenotypes observed under the influence of VEGF-B signaling, together with 
the increase in hypoxia and expansion of tumor-associated Mφ, which both have been linked 
to tumor cell dissemination, promoted us to investigate the metastatic potential in our 
available models. In the first model, blood was collected from tumor-bearing mice and 
analyzed for CTCs. For MDA-MD-435 tumors where VEGF-B had been downregulated, we 
saw a significant reduction in CTCs compared to controls. In contrast, the overexpression of 
VEGF-B in UACC-62 and fibrosarcoma tumors contributed to increased number of CTCs. 
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These indications of tumor cell dissemination were also correlated to the degree of pulmonary 
metastasis in all three models, where knock-down reduced the metastatic incidence, and 
overexpression led to increased metastasis. 
The influence of VEGF-B on the vasculature has previously been indicated to occur through 
a VEGF-A-dependent mechanism. Here, we took advantage of a murine tumor cell line, 
528ras, that lacks VEGF-A expression (originating from a VEGF-A null mouse). These cells 
were propagated to express VEGF-B and subsequently implanted into mice. Although many 
parameters were similar as detected in the previous VEGF-A positive tumors, there were 
important differences. Unexpectedly, the vasculature displayed a disorganized phenotype in 
VEGF-B expressing tumors, which is in contrast to previous models, suggesting that the 
effects of VEGF-B on vascular remodeling occurs in collaboration with VEGF-A. Although 
the perfusion and hypoxia did not differ between the two groups, permeability was increased 
and vascular coverage was reduced. The population of tumor-associated Mφ, however, was 
still increased. Importantly, independent of VEGF-A, VEGF-B promoted tumor cell 
dissemination as we detected increased CTCs and pulmonary metastasis. This effect of 
VEGF-B was confirmed in a model where we treated T241 tumors with anti-VEGF-A 
neutralizing antibody. Here, again, VEGF-B still promoted metastasis.  
VEGF-B is known to interact with VEGFR1 to convey its biological signals. So we took an 
approach where T241 tumors were implanted in VEGFR1-TK knockout mice. Tumors 
generated in these mice were to a large extent similar to tumors grown in wild-type mice, 
where VEGF-B altered the tumor microenvironment, including Mφ, and promoted 
metastasis. These findings indicate that VEGF-B in the tumor setting, is promoting metastasis 
via, at least in part, a VEGFR1-independent mechanism. 
Finally, to validate if there was any clinical relevance of our findings, we analyzed the 
correlation of VEGF-B expression and survival. Patients in high expression groups of 
melanoma and lung cancer were found to have significantly poorer survival rates. 
In summary, we identify VEGF-B as a promoter of metastasis by modulating the tumor 
microenvironment, including altering the vascular phenotype and increasing the population 
of tumor-associated Mφ. We further demonstrate that pro-metastatic effects of VEGF-B is 
independent of VEGF-A and VEGFR1 activation. Clinically, patients with high levels of 
VEGF-B had decreased survival, hence, suggesting that VEGF-B is a marker of poor 
prognosis. 
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3.4 PAPER IV 
VEGFR3 mediates FGF-2 induced lymphangiogenesis and metastasis 
Tumor cell dissemination into the lymphatic system is commonly detected in cancer patients. 
VEGF-C is the main pro-lymphangiogenic factor, but members of other growth factor 
families, including FGF-2, have demonstrated lymphangiogenic properties. Several factors 
are simultaneously co-expressed in the tumor microenvironment, but little is generally known 
about any potential interplay. Results from one previous study indicated that there might be 
a link between VEGF-C and FGF-2 signaling, as FGF-2-induced lymphangiogenesis could 
be blocked by VEGFR3 inhibition153. In this study, we aimed to further investigate the 
underlying mechanisms of FGF-2-induced lymphangiogenesis and potential involvement of 
VEGF-C/VEGFR3 signaling. 
For initial studies, we chose to use an established mouse cornea assay model to investigate 
the angiogenic effects of VEGF-C and FGF-2. The cornea is providing an advantageous 
system to study angiogenesis in vivo by its nature of being an avascular tissue315. Here, the 
factors were implanted as pellets in the avascular cornea and allow for studies of blood and 
lymph vessel growth. We confirmed the individual pro-angiogenic and lymphangiogenic 
properties of VEGF-C and FGF-2. To our surprise, co-implantation of both factors resulted 
in synergistic effect on both angiogenesis and lymphangiogenesis. 
Next, we performed in vitro studies to gain further understanding of the synergism on a 
cellular level. For these experiments, we used primary mouse and human LECs. Both VEGF-
C and FGF-2 induced proliferation in mLECs and hLECs, demonstrating that both factors 
are directly effecting these cells. This effect was significantly potentiated upon co-
stimulation. Further experiments demonstrated that mainly FGFR1 was expressed, whereas 
FGFR2-4 were barely detectable, indicating that the FGF-2-FGFR1 axis was responsible for 
FGF-2 induced effects. Interestingly, qPCR analyses demonstrated that FGFR1 levels were 
increased by both VEGF-C and FGF-2 stimulation. Similarly, both factors also upregulated 
VEGFR3 expression. These results suggest a reciprocal amplification of the receptors 
induced by the ligands. 
To study the involvement of VEGFR3 and FGFR1 in mediating biological processes upon 
stimulation, we used specific receptor neutralizing antibodies. FGF-2-induced proliferation 
and migration of mLEC was completely blocked by the addition of an anti-FGFR1 antibody, 
but no significant inhibitory effects upon VEGFR3-blockade. Opposite findings were 
observed with VEGF-C stimulation as only VEGFR3 neutralizing antibody had inhibitory 
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effects. Collectively, in vitro experiments indicate that these ligands are exerting the 
lymphangiogenic activities via their own receptor-specific axis. 
Moving back to the cornea assay, to verify the role of FGFR1 in transducing FGF-2 activities 
in vivo, we co-implanted VEGF-C and FGF-2 and treated with the anti-FGFR1 neutralizing 
antibody. FGFR1-blockade significantly inhibited angiogenesis and lymphangiogenesis. 
Furthermore, we applied VEGFR3-blockade and could observe complete inhibition of 
VEGF-C-induced lymphangiogenesis. Unexpectedly, VEGFR3-blockade also significantly 
inhibited FGF-2-induced lymphangiogenesis. To understand how VEGFR3 is involved in 
FGF-2 promoted lymphangiogenesis, we took a closer look at the tip cells, as it was reported 
that tip cell formation is crucial for the angiogenic process. Individually, both VEGF-C and 
FGF-2 could induce tip cells in the growing lymph vessels. Co-implantation significantly 
contributed to an additive effect. Surprisingly, VEGFR3-blockade completely suppressed 
lymphatic tip cell formation in all conditions (FGF-2/VEGF-C/VEGF-C+FGF-2), but no 
inhibition was detected for blood vessel growth. These results are suggesting that FGF-2-
promoted lymphangiogenesis is dependent on VEGFR3 for tip cell formation. In addition, 
we demonstrated that VEGF-C stimulates angiogenesis through activating VEGFR2, rather 
than VEGFR3. 
Based on these initial findings, we wanted to investigate the effects of VEGF-C and FGF-2 
in the tumor setting to study lymphangiogenesis and metastasis. For this purpose, we 
propagated a murine fibrosarcoma cell line, T241, to overexpress (and secrete) FGF-2 or 
VEGF-C. Implantation of these cells into mice showed that both VEGF-C and FGF-2 
individually are promoting tumor growth, angiogenesis, and intratumoral 
lymphangiogenesis. Interestingly, all these processes were significantly potentiated beyond 
the additive effects when implanting a mixture of VEGF-C and FGF-2 expressing tumor 
cells, demonstrating collaborative effect of the two factors. Finally, as our previous findings 
clearly showed that both blood and lymph vessels were promoted in these models, we sought 
to examine the metastatic capacity. Individually, mice with VEGF-C expressing tumors 
displayed more metastatic burden in lungs and lymph nodes compared to FGF-2 implanted 
tumors. Notably, co-implantation of VEGF-C and FGF-2 expressing tumor cells drastically 
increased the number of visible metastatic nodules present in the lungs, and all mice in this 
group developed lymph node metastasis.   
In summary, there is a clear microenvironmental interaction between different factors that 
regulate various processes in the tumor. Here, we revealed the underlying mechanisms of 
FGF-2-induced lymphangiogenesis by showing how VEGFR3-blockade completely 
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inhibited lymphangiogenic sprouting upon FGF-2 stimulation in vivo in both cornea and 
tumor models. We showed that tip cell formation is dependent on VEGFR3 activation. 
Furthermore, we identified how VEGF-C and FGF-2 are reciprocally amplifying each other’s 
signaling to synergistically promote blood and lymph vessel growth, leading to metastasis. 
Collectively, our results demonstrate the importance of microenvironmental communication 
between growth factors in tumors. Therefore, combination therapy should be designed to 
interfere with such interplay. 
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4 DISCUSSION AND CONCLUSIONS 
Metastatic disease is responsible for the majority of cancer-related deaths and the underlying 
mechanisms for tumor cell dissemination remains largely unknown. Increasing evidence is 
indicating how non-malignant cells of the host are contributing to a pro-metastatic 
phenotype227. Continuous efforts are being put on understanding the communication between 
compartments in the tumor microenvironment. The tumor microenvironment is highly 
complex, consisting of various cellular types, including ECs, PCs, VSMCs, fibroblasts, and 
immune cells. These cells are responsible for growth of blood and lymph vessels, generating 
connective tissues, and inflammation. The microenvironment provides, as previously 
mentioned, an opportunity for therapeutic intervention. By increasing the knowledge behind 
microenvironmental communication, we can begin to understand how to optimally block 
tumor-promoting processes.  
 
Therapeutic targeting aiming to alter the density and structures of blood vessels to become less 
accessible to tumor cell intravasation would decrease metastasis and increase patient survival. 
It has proven not to be that straight-forward, as we provide several examples of in our current 
work, and additional efforts are needed. Can use vascular targeting and remodeling to reduce 
vascular density and improve the quality of the vessels that do remain? So far, the clinical 
experience of anti-angiogenic targeting has reduced the interest of such approaches. If anti-
angiogenic and angiogenesis-modulating therapies are applied in the right setting, tumor would 
struggle to survive. The questions are when and how to treat. Anti-angiogenic therapy can be 
applied by different strategies. Either directly targeting the ECs by modulating the 
VEGFs/VEGFRs signaling axis, or by indirect targeting of the vascular support cells. Anti-
PDGF targeting is one example of the latter. Clinically, several drugs are available that prevent 
activation of PDGFRs, including imatinib, sunitinib, and sorafenib. Except for imatinib in 
treatment of leukemia (blocking Bcr-Abl in CML), there is no molecular indication for their 
use in specific patients, pointing-out the need for new understanding of the underlying 
mechanisms. We sought to investigate the underlying principles for PDGF-BB signaling in 
tumors. In paper I, we report how one growth factor, PDGF-BB, produce opposing outcomes 
depending on its expression level, especially following therapeutic intervention using imatinib. 
On one hand, PDGF-BB is frequently expressed in tumors and its biological effects are 
mediated by directly acting on PDGFR-β expressing cells, such as PCs. Interestingly, in 
contrast to the role in recruitment of PCs to vessels, we found that high levels of PDGF-BB 
decreased vascular coverage and increased vessel disorganization. We identify a functional link 
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relating PDGF-BB signaling and the impairment of integrin interaction between ECs and PCs, 
leading to detachment of PCs. Consequently, the metastatic potential is increased in these 
tumors. These results are indicating that PDGF-BB signaling should be targeted in cancer 
patients. Our findings, however, demonstrated that the issue is more complex. In tumors where 
PDGF-BB is relatively low, anti-PDGF targeting is causing metastasis rather than having an 
anti-tumorigenic effect. Similar mechanisms could be true for other factors as well, indicating 
the importance of understanding the context-dependent outcomes before applying any type of 
therapy. Collectively, we point-out the need of a clear indication for therapy. In the clinical 
setting, it can be difficult to justify the use of a specific therapeutic agent. Many patients are 
found to be non-responsive to the treatment and there is a need for improvements in selection 
of patients. Reliable biomarkers that can predict treatment outcome and select patients that will 
benefit from a certain treatment. Here, we identify PDGF-BB as a potential biomarker for anti-
PDGF targeting therapy. 
In tumors, there are both direct and indirect mechanisms for regulation of various processes. 
For example, blood vessels are carriers of oxygen, hence, direct targeting of blood vessels, will 
indirectly lead to increased hypoxia, which is responsible for many tumor promoting processes. 
Hypoxia is involved in the regulation of PDGF-BB expression132, 133. The contributions of 
PDGF-BB to the tumor tissue, in addition to the extensively studied effects on PCs, are not 
clear. Growth factors, such as PDGF-BB, are not only potently regulating the functions of 
cellular populations through their specific receptor signaling axis, but indirect mechanisms are 
equally important. It will be essential to understand the secondary impacts of signaling by one 
factor, in addition to the direct effects in targeted cells. This could provide novel strategies for 
therapy. We exemplify such complex interaction using PDGF-BB as we previously noticed 
that PDGF-BB signaling in tumors is contributing to increased numbers of Mφ despite the lack 
of PDGFR expression by this cell type. In paper II, we report a previously unknown mechanism 
of PDGF-BB-induced Mφ infiltration. By activation of PDGFR-β-positive cells, PDGF-BB is 
stimulating the production of IL-33. In turn, IL-33 is regulating different populations of cells 
that express the ST2 receptor, including Mφ. Interestingly, not only numbers of Mφ were 
increased, but we also detected a clear polarization towards M2 phenotype. Many publications 
have indicated that M2 Mφ have tumor promoting functions and are important in the metastatic 
process. In our models, we confirmed the contributions of tumor-associated Mφ to metastasis, 
demonstrating that the metastatic potential of PDGF-BB is mediated through Mφ via IL-33 
signaling. The question that remains to be addressed is how Mφ are facilitating metastasis. Are 
there unidentified mechanisms in addition to the ones that have been reported? Even without 
further understanding, the population of Mφ, on its own, is emerging as an important target for 
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prevention of metastasis. Here we identify and highlight a link between the growth factor 
signaling and cytokine systems, indicating the importance of microenvironmental interplay. 
Essentially, our findings could provide a new therapeutic opportunity, especially in 
inflammatory-driven tumors. Whereas anti-PDGF targeting is already established, targeting of 
Mφ is currently being developed by different strategies and it will be interesting to follow 
clinical trials using such therapies. We show how IL-33 drives the increase of Mφ and is 
responsible for polarization towards M2, hence, targeting of IL-33 would offer an upstream 
approach to prevent tumor-associated Mφ. Blocking IL-33 signaling would be feasible by 
neutralizing antibodies or soluble receptor protein. In fact, recently it was announced that 
AnaptysBio is entering an IL-33 neutralizing antibody (ANB020) in phase I clinical trials 
aiming for patients with asthma, atopic dermatitis and peanut allergy (Clinical Trial ID: 
NCT02920021). An application in cancer would be an interesting addition and, based on our 
results, potentially useful for preventing metastasis. 
The blood vascular system is a common route of dissemination and angiogenesis is a pre-
requisite for growth of a solid tumor. In addition to diverse vascular phenotypes being 
generated during the sprouting of vessels under influence of different factors, where VEGF-A 
is known to generate a disorganized tumor vascular network, there is an important contribution 
of vascular remodeling314. Much remains to be learnt about the regulation of this process and 
its involvement in tumor progression. In paper III, we demonstrate how VEGF-B promotes 
metastasis by modulating the tumor vasculature and inflammation. Importantly, gross 
examination of the vascular structures generated under the influence of VEGF-B signaling, 
appeared to be normalized. When analyzing the vessels, we could identify a poor vascular 
coverage and impaired EC junctions, leading to a leaky and tumor cell-accessible vessel 
structure. This finding pointed-out that vascular density and degree of disorganization, in terms 
of branch-points, cannot reliably be used for metastatic prediction. In combination with an 
altered tumor microenvironment, including vascular remodeling, increased numbers of Mφ and 
increased hypoxia, despite simultaneously retarding tumor growth, VEGF-B potently 
promoted metastasis. Collectively, VEGF-B exemplifies the difficulty of tumor biology. 
Tumors are inhibited in their growth, which is a good clinical sign, and vascular density is 
reduced, but tumors are still metastatic. Further efforts are needed to understand how these 
processes are being uncoupled. Of importance for targeting of VEGF-B signaling in tumors, 
even with being identified as only binding to VEGFR1, in this work, we demonstrated that 
VEGF-B-induced metastasis is VEGFR1-independent. These results are suggesting that 
intracellular targeting of VEGFR1 by small molecules, would not effectively block the pro-
metastatic properties of VEGF-B. Additional studies are needed to identify a potential receptor 
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mediating these VEGFR1-independent processes of VEGF-B. Such findings would discover a 
novel target for prevention of metastasis.  
One additional important compartment of the tumor microenvironment and a common route of 
dissemination, is the lymphatic system. Cancer patients often develop lymph node metastasis316 
and will, in for example breast cancer, frequently undergo surgery to remove sentinel lymph 
nodes along with the primary tumor. The main system for regulation of lymphangiogenesis is 
VEGF-C/VEGFR3 signaling, although additional factors also have pro-lymphangiogenic 
properties. Further complicating the matter, is the fact that many factors are simultaneously 
expressed in the tumor tissue. The possible relationship between signaling pathways in regards 
to angiogenesis and dissemination is unclear, but potentially important for resistance and 
treatment outcome. Clinically, this issue is not addressed. In paper IV, we identify a synergistic 
interplay of two growth factors, VEGF-C and FGF-2, in promoting metastasis by 
collaboratively inducing blood and lymph vessel growth. The most important conclusion from 
our experiments is the demonstration how VEGFR3-blockade is able to completely prevent 
FGF-2-induced lymphangiogenesis. Importantly, blood vessel growth promoted by FGF-2 is 
VEGFR3-independent and instead meditated by FGFR1 activation. These findings are showing 
that lymphangiogenesis is triggered in a sequential process and that VEGFR3 is essential for 
the initial step, the tip cell formation. This would suggest that VEGFR3-targeting, 
irrespectively of the driving force, will be important in tumors with high potential to induce 
lymphangiogenesis with subsequent lymphatic dissemination. Importantly, our findings are 
showing that FGF-2-induced blood vessel growth is independent of VEGFR3-activation. 
Collectively, it is becoming evident that combinational targeting will be necessary to prevent 
interplays such as these.  
In this thesis work, we identify new concepts in tumor biology by revealing previously 
unknown mechanisms:  
 High levels of tumor-derived PDGF-BB lead to reduced vascular coverage and 
facilitated tumor dissemination. We suggest to use PDGF-BB as a biomarker for anti-
PDGF therapy  
 IL-33 as a novel potential therapeutic target for inflammation-induced metastasis  
 VEGF-B as a promoter of metastasis through a VEGFR1-independent mechanism 
 VEGFR3-activity as being required for lymphatic tip cell formation, even under non-
VEGFR3-ligand stimulation 
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In conclusion, we identify how tumors are employing different mechanisms for supporting the 
metastatic process by modulating different aspects of the tumor microenvironment. There is no 
effective treatment currently available for patients with metastatic disease. By characterizing 
the common factors expressed in tumor tissues and revealing the underlying mechanisms of 
the involvement of the tumor microenvironment, we can define new targets and strategies for 
therapy. Prevention of tumor cell dissemination will be critical to reduce mortality. 
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